Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

277.90 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 582
Open 277.90
Bid (Size) 276.55 (1)
Ask (Size) 279.55 (2)
Prev. Close 277.90
Today's Range 277.90 - 277.90
52wk Range 253.30 - 346.85
Shares Outstanding N/A
Dividend Yield 3.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is the Market Bullish or Bearish on Amgen?
Via Benzinga
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political

Performance

YTD
+7.18%
+7.18%
1 Month
-11.60%
-11.60%
3 Month
+1.63%
+1.63%
6 Month
-11.75%
-11.75%
1 Year
+1.59%
+1.59%

More News

Read More
Amgen, Franco-Nevada, Take-Two Interactive And More: CNBC's 'Final Trades'
Via Benzinga
Short Week Finishes With Netflix Q1 Beat
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Via Benzinga
P/E Ratio Insights for Amgen
Via Benzinga
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Sandoz Files Antitrust Lawsuit Against Amgen Over Inflammation Drug, Seeks Damages: Retail Sentiment Falters
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury
Via Investor's Business Daily
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Rule Breaker Investing: Essays From Yesterday, Vol. 7
Via The Motley Fool
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Topics Economy Intellectual Property
Exposures Economy Intellectual Property
2 Dividend Stocks to Buy Hand Over Fist in April
Via The Motley Fool
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks
Via Benzinga
Topics Economy Stocks World Trade
Exposures Interest Rates Tariff US Equities
FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
Via Benzinga
Exposures Product Safety
Amgen Stock Edges Higher After Uplizna Becomes First FDA-Approved Treatment For Immune-Mediated Disorder – Retail Gets More Bullish
Via Stocktwits
Topics Government World Trade
Exposures Political Product Safety Tariff
Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
Via Benzinga
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Political Tariff
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.